Current Report Filing (8-k)

Date : 05/17/2019 @ 9:32PM
Source : Edgar (US Regulatory)
Stock : Atossa Genetics Inc (ATOS)
Quote : 2.08  0.02 (0.97%) @ 12:11AM

Current Report Filing (8-k)

 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): May 16 , 2019

 

Atossa Genetics Inc.

(Exact name of registrant as specified in its charter)

 

 

 

 

 

Delaware

 

001-35610

 

26-4753208

(State or other jurisdiction of
incorporation)

 

(Commission File Number)

 

(I.R.S. Employer
Identification No.)

 

107 Spring Street

Seattle, Washington

 

98104

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (206) 325-6086

 

Not Applicable
Former name or former address, if changed since last report

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuance to Section 12(b) of the Act:

 

Title of each class

Trading symbol(s)

Name of each exchange on which registered

Common Stock, $0.18 par value

ATOS

NASDAQ

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

 

Emerging growth company    ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

 

 

 

 

Item 5.02

Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; and Executive Compensation Agreements

 

On May 16, 2019, the Compensation Committee of the Board of Directors completed its review and assessment of the 2018 performance of Steven C. Quay, MD, Ph.D., Chairman, CEO and President, and Kyle Guse, CFO, General Counsel and Secretary, and determined the amount of their 2018 bonuses which are $291,000 and $183,600, respectively. Taking into account these amounts, the total compensation that would have been reported in the summary compensation table for 2018 for Dr. Quay was $2,172,344 (which includes an option valued at $1,081,019 that was cancelled on January 13, 2019 and replaced with a similar option that was contingent on stockholder approval) and for Mr. Guse was $1,088,931 (which includes an option valued at $329,006 that was cancelled on January 13, 2019 and replaced with a similar option that was contingent on stockholder approval).

 

Item 5.07 Submission of Matters to a Vote of Security Holders

 

On May 16, 2019, the Company held its 2019 Annual Meeting of Stockholders (the “ Annual Meeting ”). The following items of business were considered and voted upon at the Annual Meeting: (1) the election of two Class I directors named in the proxy statement related to the Annual Meeting; (2) the ratification of the selection of BDO USA LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019; (3) the approval of the 2019 amendments to the Atossa Genetics Inc. 2010 Stock Option and Incentive Plan and to increase the number of authorized shares for issuance under the Plan by 3,600,000 shares; (4) to conduct an advisory (non-binding) vote on the compensation of our named executive officers as described in the proxy statement related to the Annual Meeting; (5) an advisory (non-binding) vote on the frequency of future advisory votes on executive compensation; and (6) the transaction of any other business that may properly come before the meeting or any adjournment thereof.

 

The number of shares of common stock entitled to vote at the Annual Meeting was 9,124,447. The number of shares of common stock present or represented by valid proxy at the annual meeting was 7,210,260. All proposals passed. The number of votes cast for and against, and the number of abstentions and broker non-votes with respect to the matters voted upon at the Annual Meeting, are set forth below: 

 

(i)

Election of two Class I Directors

 

The stockholders elected two Class I directors as set forth below:

 

Nominee

Votes For

Votes
Withheld

Broker  

Non-Votes  

Steven C. Quay, M.D., Ph.D.

1,959,851

191,525

5,058,884

Gregory L. Weaver

1,936,615

214,761

5,058,884

 

(ii)

Ratification of Auditors

 

The stockholders ratified the appointment of BDO USA LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019 as set forth below:

 

Votes For

Votes Against

Abstain

Broker
Non-Votes

6,810,642

247,416

152,202

0

 

(iii)

Approve the 2019 amendments to the Atossa Genetics Inc. 2010 Stock Option and Incentive Plan and to Increase Authorized Shares under Option Plan

 

The stockholders approved the amended 2010 Stock Option Plan and an increase of 3,600,000 shares to the option plan as follows:

 

Votes For

Votes Against

Abstain

Broker
Non-Votes 

1,100,738

1,009,939

40,699

5,058,884

 

(iv)

Non-binding Vote on Executive Compensation

 

The stockholders approved an advisory non-binding vote on executive compensation as follows:

 

Votes For

Votes Against

Abstain

Broker
Non-Votes

1,354,683

717,441

79,252

5,058,884

 

(v)

Non-binding Vote on Frequency of Say-on-Pay

 

The stockholders approved an advisory non-binding vote on the frequency of the vote on executive compensation as follows:

 

Annual

Biennial

Triennial

Abstain

Broker
Non-Votes

1,615,371

73,626

238,949

223,430

5,058,884

 

 

* * *

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

Date: May 17, 2019

Atossa Genetics Inc. 

 

 

 

 

 

By:  

/s/ Kyle Guse 

 

 

 

Kyle Guse

 

 

 

Chief Financial Officer, General Counsel and Secretary 

  

 

 

Atossa Genetics (NASDAQ:ATOS)
Historical Stock Chart

1 Year : From Sep 2018 to Sep 2019

Click Here for more Atossa Genetics Charts.

Atossa Genetics (NASDAQ:ATOS)
Intraday Stock Chart

Today : Sunday 22 September 2019

Click Here for more Atossa Genetics Charts.

Latest ATOS Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.